The Kevin Trudeau Show: 4-6-13
Today, Kevin delves deep into the obesity epidemic in America. Plus, find out how Kevin Trudeau would run The United States of America if he were president!
Self Help:
Loss Weight Right!
Emergency Preparedness
Trace Minerals
Health:
The Worst Food In America
Worker Dies at Cubicle, Found a Day Later
Light Bulbs Advertised as ‘Green’ Contain Arsenic and Lead
The Weight-Loss Industry Makes Huge Gains
111 Health Care Professionals Charged in $225 Million Medicare Scam
Wealth:
US Debt Clock
Danger! Falling Incomes!
First Premier Bank Removes Credit Card With 59.9% APR
Government:
Judge Found Guilty of Racketeering & Tax Fraud
TSA Screening Supervisor Admits to Stealing from Passengers
NWO:
Scientists Warn of Solar ‘Katrina’
Everything Kevin:
Become An Insider!
Support Kevin!
Kevin is on YouTube!
Sign Up For Kevin’s FREE Podcast
Follow Kevin on Twitter
Become A Fan of Kevin on Facebook
Take Trudeau on the Go! Click here to download this show to your iPod, mp3 player, or PC through iTunes!
Click Below to Watch the Kevin Trudeau Show LIVE!
The Kevin Trudeau Show: 7-7-12
On this weekend’s edition of The Kevin Trudeau Show, Judge Andrew Napolitano stops by to expose why your freedoms are being forfeited by a government that is more protective of its own power than its constitutional promise to preserve your individual liberties. Click here to purchase his new book, Lies The Government Told You.
PLUS, The Water Doctor, Fred Van Liew, discusses John Stossel’s bunko assertions that plastic bottles don’t cause health problems and that tap water is healthy. Click here to save yourself from the toxins lurking in your water supply!
Food:
Junk Food-Addicted Rats Chose to Starve Rather Than Eat Healthy Food
General Bans Booze & Junk Food
Gordon Ramsay Restaurants Uses Pre-Prepared Meals
Customer Flips Over Filet-O-Fish
Drugs:
Antibiotics Linked to Increased Risk of Birth Defects
Study Urges Vitamin D Supplement for Infants
Cholesterol Drug Use Risky For Healthy People
Vitamin B3 Beats Big Pharma’s Cholesterol Drug
Government:
FDA Suppressed Imaging Safety Concerns
Cuban Leader Endorses Obama Health Care Reform
Expert Claims of Livestock Causing Global Warming False
Record Number of Journalists Murdered Last Year
Health:
Papaya is Effective Against Certain Cancers
Everything Kevin:
Become An Insider!
Support Kevin!
Kevin is on YouTube!
Sign Up For Kevin’s FREE Podcast
Follow Kevin on Twitter
Become A Fan of Kevin on Facebook
Kevin’s Film Club
Kevin’s Book Club
Take Trudeau on the Go! Click here to download this show to your iPod, mp3 player, or PC through iTunes!
Click below to watch the Kevin Trudeau Show!
Anti-Diabetes Drugs May Cause Diabetes
March 8, 2012 by admin
Filed under News Stories
March 8, 2012
NaturalNews.com
By D Holt
Statin drugs are prescribed to lower cholesterol in the UK for obese patients, and also to those who have type-2 diabetes. But according to the Food and Drug Administration in the USA there is a risk of developing diabetes if you take statins — so much so that the FDA has demanded that warnings of the risk of the development of diabetes on put the labels of statin drugs distributed within the US. In the UK, however,there has been a reluctance to include a labelling policy as it would cause patients to be adverse to their treatment.
The link is a ‘statistical’ one; there is an increased risk of being affected by the risk of diabetes if you take the medicine. However, the link between the medicine and the side effect is severe enough for the FDA to act, which is a factor that the UK government seems to disregard. Other cases of this disregard forthe research of othernations includes the banning of all except eight artificial food colors in the USA and other nations,whereas the UK still allows several of these banned colors to remain on the market.
Click here for the full report from NaturalNews.com
FDA To Reconsider Once-Rejected Diet Drug
February 17, 2012 by admin
Filed under News Stories
February 17th, 2012
ABC News
By: Carrie Gann
In the search for treatments to fight obesity, regulators are turning their attention to a diet drug that has already failed to receive government approval as a weight loss treatment.
Next week, a panel of advisors to the U.S. Food and Drug Administration will consider whether or not to recommend the diet drug Qnexa for approval. The move is the latest attempt to give new tools to patients and doctors to fight the obesity that currently plagues one-third of Americans. It also fans a fiery debate about the search for a “magic bullet” alternative to difficult lifestyle changes to help obese people lose weight.
Qnexa was rejected by the FDA in 2010 over concerns about potentially dangerous side effects, such as cardiovascular problems and birth defects. Now, the FDA will consider whether or not the drug’s manufacturer, Vivus, should do a larger clinical trial to investigate the potential for cardiovascular side effects.
But some obesity specialists are, in effect, already giving the drug to their patients by prescribing Qnexa’s two major ingredients, phentermine and topiramate. The practice, called off-label prescribing, is not prohibited by the FDA. Doctors who have prescribed this combination say it has helped patients shed pounds when many other paths to weight loss have failed.
Dr. Ken Fujioka, director of the Center for Weight Management at Scripps Clinic in San Diego, said he often sees obese patients who have changed their diets, started exercising more and still have not been able to lose more than a few pounds. Though bariatric surgery is a lasting, effective option for long-term weight loss, many patients either aren’t morbidly obese enough to qualify for the surgery or are reluctant to resort to such a drastic measure to lose weight. For about 30 of these patients, Fujioka has prescribed low doses of phentermine and topiramate.
“The weight loss with this combination rivals bariatric surgery and I see using these meds in the seriously obese patient as an alternative,” Fujioka said.
Dr. Jana Klauer, a New York City-based doctor specializing in weight management, said her patients lost an average of 40 pounds when taking the drugs along with improved diet and exercise plans.
“The drug combination gives great results, providing diet and exercise are part of the plan,” she said.
Vivus, the company that developed Qnexa, said in a statement that the drug is a combination of low doses of both drugs and it is intended for use in combination with improvements in diet and exercise. Vivus said it does not support the off-label use of phentermine and topiramate.
The drugs work by suppressing appetite, and both have been approved by the FDA for other uses. Phentermine, a stimulant, is already approved for weight loss, but only for short-term use. Topiramate is an anticonvulsant, for which weight loss is a side effect.
But a laundry list of side effects has many experts concerned about the safety of the drugs, if taken over a long period of time. Topiramate creates feelings of mental fogginess, memory lapses and a lack of concentration.
Phentermine, one of drugs that made up the failed diet drug Fen-Phen, can lead to a range of cardiovascular side effects, such as high blood pressure, heart attacks and heart palpitations. Dr. David Katz, co-founder of the Yale University Prevention Research Center, noted that these side effects are the very problems caused by obesity.
Dr. Charles Clark, a professor of pharmacology and toxicology at Indiana University, said the potential side effects are enough to keep him from prescribing phentermine and topiramate to his patients, particularly in light of the failure of Fen-Phen, which was withdrawn from the market in 1997 after causing fatal blood pressure and heart valve problems in patients.
“Given our experience with Fen-Phen, we should be cautious in our use of these agents until larger and longer-term trials are completed,” Clark said.
Others say concerns about side effects of both drugs and their offspring Qnexa are legitimate, but could be managed or avoided if doctors carefully monitor patients while they’re taking the drug. For example, the FDA’s concerns about potential birth defects caused by Qnexa could be resolved by not prescribing the drug to women who could get pregnant. Many doctors say the risks of these drugs may be outweighed by the benefits for some patients with disabling health problems caused by obesity.
In the past 20 years, a parade of diet drugs have come before the FDA, representing an effort by drug companies to give obese patients and their doctors alternatives to difficult, often unsuccessful lifestyle changes. Most of the drugs have failed to meet the agency’s standards for safety and effectiveness. Many come with a list of embarrassing side effects, such as anal leakage, and only one, Alli, is approved for long-term use. A handful of drugs, such as Metabolife and Meridia, were removed from the market because of heart safety concerns.
Some doctors say there is no evidence that Qnexa will perform better than the diet drugs that have already flopped.
“I have made selective use of some weight loss drugs, but have not to date found much reason for enthusiasm for any of them,” Katz said. “I don’t have much for Qnexa.”
Others are more hopeful that Qnexa is different, including Dr. Chip Lavie, medical director of cardiac rehab and prevention at the Ochsner Clinic Foundation in New Orleans. He cites evidence from previous clinical trials that Qnexa helps patients lose a modest amount of weight, which improves their risk factors for diabetes, high blood pressure and other cardiovascular problems. He said cardiovascular and birth defect risks that the FDA cited in its first look at the drug were very slight and “clinically unimportant.”
“Considering the dismal results that many experience with attempted weight loss with diet and exercise, which is always the first choice, and the explosion in the need and use of bariatric surgery, this combination drug should be a major advance, and I hope that it gets approved this time by the FDA,” Lavie said.
For The Full Report Go To ABC News
Feds Succeed In Destroying Entire Business Of Amish Raw Milk Farmer
February 17, 2012 by admin
Filed under News Stories
February 17th, 2012
Natural News
By: Ethan A. Huff
It is with much sadness that we report the two-year war waged by the U.S. Food and Drug Administration (FDA) against Pennsylvania Amish farmer Dan Allgyer has been a success.The Washington Timesand others are now reporting that, following a ruling last month by Judge Lawrence F. Stengel that Allgyer could no longer ship raw milk across state lines, he is officially shutting down his entire Rainbow Acres Farm.
Provoking Allgyer to shut down his farm appears to have been the goal of the FDA all along, which back on February 4, 2010, conducted a gestapo-style raid on Allgyer’s Kinzers, Penn., property to search for evidence that he was shipping raw milk across state lines. After illegally trespassing on the man’s property, the agents proceeded to harass Allgyer about his supposed involvement in interstate commerce (http://foodfreedom.wordpress.com).
Just a few months later on April 20, 2010, the FDA again sent its Nazi-sympathizing thugs back to Rainbow Acres Farm, this time at 4:30 a.m. while Allgyer was still asleep, to conduct another raid. Violating the provisions of their so-called warrant, which specified that any inspection must be conducted during “reasonable times during ordinary business hours,” the agents proceeded to once again ransack the farm in search of evidence to back their claims that Allgyer was engaged in illegal interstate commerce (http://www.naturalnews.com/029322_raw_milk_Amish.html).
Following this second sting, the FDA claims to have discovered the evidence it needed, and immediately sent Allgyer a warning letter notifying him that he was in violation of interstate commerce laws, according to their view (http://www.farmtoconsumer.org/aa/aa-26april2010.htm). The agency also filed a civil complaint against Allgyer around the same time.
With hundreds of happy and satisfied out-of-state customers that relied on him for fresh supplies of raw milk, Allgyer attempted to satisfy the FDA’s demands by restructuring his farm’s distribution process into private cow share agreements with customers. Such agreements allow individuals to directly purchase shares in the cows from which they get milk, which means they personally own them, and they are not subject to FDA jurisdiction.
Rogue judge essentially declares FDA has jurisdiction over private property use, in this case cows
But on February 3, 2012, Judge Stengel decided that Allgyer was still in violation of interstate commerce laws,even with the restructured cow sharing arrangements, and ordered him to stop distributing raw milk altogether. Private cow share agreements do not constitute interstate commerce, of course, but Judge Stengel apparently pays no regard to individual liberty, having declared that the FDA basically now has jurisdiction over private property use.
Likely worn down from the perpetual and never-ending harassment, Allgyer appears to have decided to simply give up trying to fight this unprecedented tyranny, and simply shut down his farm. Hundreds of families that relied on Allgyer for fresh milk, butter, cheese, eggs, and other nutritious goods will now have to find a new source for clean food, at least until the FDA shuts them down, too.
“I can’t believe in 2012 the federal government is raiding Amish farmers at gunpoint all over a basic human right to eat natural food,” said one of the farm’s former customers, who wished to remain anonymous, toThe Washington Times. “In Maryland, they force taxpayers to pay for abortions, but God forbid we want the same milk our grandparents drank.”
For The Full Report Go To Natural News
Pharma Phonies? Prescription Drugs That Lead Double Lives
February 9, 2012 by admin
Filed under News Stories
February 9th, 2012
CBSNews.com
By: CBS News Staff
We usually view side effects as a bad thing, but sometimes they point the way to a whole new use for a drug.
“We think of drugs as being specific to a task,” says Dr. Jeremy Greene, Harvard University medical historian. In fact, he says, “drugs are very complex objects.”
As research and development costs have climbed, drug companies are more interested than ever in finding ways to repurpose their products. Often they seek to simply market an existing drug for a new condition, but in some cases they give the drug a whole new name and face. From our friends at Health.com, here are eight drugs that lead double lives…
The first on the list? Prozac, which is also sold as Sarafem.
Click here for the full report
Anti-Cancer Drug For Women Weakens Bone Density
February 7, 2012 by admin
Filed under News Stories
February 7, 2012
By Agence France-Presse
A drug tipped for widespread use to prevent breast cancer in post-menopausal women also accelerates loss of bone density, thus potentially boosting the risk of fractures, a study published on Tuesday said.
Exemestane — brand name Aromasin — is part of a drug class called aromatase inhibitors, which lower levels of the oestrogen that some breast cancers need in order to grow.
Canadian bone specialists took a look at a group of patients who had taken part in a study into the effectiveness of exemestane among 4,500 healthy women with a worrying family history of breast cancer.
Overall, the big study showed that the drug was highly effective, reducing the risk of breast cancer by almost two-thirds.
Click here for the full report from The Raw Story
The Kevin Trudeau Show: 1-28-12
You will not believe what the drug companies get away with! KT explains what Big Pharma is doing to get their drugs to the mass market. Plus, Jon Rappoport stops by to blow the whistle on government corruption and media lies!
Self Help:
Your Wish Is Your Command
Health
Big Pharma Researcher Admits to Faking Research!
EU Bans Chemical BPA in Baby Bottles
Mylanta Recall Adds to Johnson & Johnson Woes
Government
FDA, WebMD Expand Health Information Partnership
Better Business Bureau Issues Mea Culpa for Pay-to-Play Ratings
Wealth
How Many Americans Don’t Pay Taxes?
Everything Kevin:
Become An Insider!
Kevin is on YouTube!
Download Kevin’s iPhone App!
Sign Up For Kevin’s FREE Podcast
Follow Kevin on Twitter
Become Kevin’s Friend on Facebook
Kevin’s Film Club
Kevin’s Book Club
Take Trudeau on the Go! Click here to download this show to your iPod, mp3 player, or PC through iTunes!
Click Below to Download the Kevin Trudeau Show!
Possible Drug Mix-up
January 10, 2012 by admin
Filed under News Stories
January 9, 2012
CNN
By Madison Park
Machinery problems at a drug manufacturing plant prompted the U.S. Food and Drug Administration to warn patients of a possible mix-up affecting various prescription pain medications and over-the-counter drugs.
The FDA is advising patients who use certain prescription medications produced by Endo Pharmaceuticals to visually inspect their pills. And consumers who have select bottles of Excedrin, Bufferin, NoDoz and Gas-X, produced by Novartis, are being told to discard or return the products in a voluntary recall that started Sunday.
The over-the-counter drugs involved in the recall were manufactured at a Lincoln, Nebraska, facility which also produced various prescription pain medicines for Endo Pharmaceuticals, according to the U.S. Food and Drug Administration. These pills include Percocet, Opana and Percodan.
“Due to problems that occurred when these products were packaged and labeled at the site, it’s possible that tablets from one product may have been retained in the packaging machinery and then may have carried over into the packaging of another product,” said Dr. Edward Cox, director of the Office of Antimicrobial Products, Office of New Drugs, Center for Drug Evaluation of Research for the FDA.
“This could result in an incorrect pill ending up in the bottle of another product. The likelihood of this occurring in medication dispensed in patients is estimated to be low,” he added.
The prescription opioids could have ended up in the bottle of another prescription drug or over-the-counter products, although “the risk of pills ending up in the wrong bottle is a rare event,” according to the FDA.
There have been no reports of adverse events due to this problem, Cox said.
Click here for the full report from CNN
F.D.A. Revokes Approval Of Avastin As Breast Cancer Drug
November 18, 2011 by admin
Filed under News Stories
November 18, 2011
The New York Times
By: Andrew Pollack
The commissioner of the Food and Drug Administration on Friday revoked the approval of the drug Avastin as a treatment for breast cancer, ruling in an emotional issue that pitted the hopes of some desperate patients against the statistics of clinical trials.
The commissioner, Dr. Margaret A. Hamburg, said that the drug was not helping breast cancer patients to live longer or control their tumors, but did expose them to potentially serious side effects such as severe high blood pressure and hemorrhaging.
“This was a difficult decision,” Dr. Hamburg, said in a statement. The F.D.A. “recognizes how hard it is for patients and their families to cope with metastatic breast cancer and how great a need there is for more effective treatments. But patients must have confidence that the drugs they take are both safe and effective for their intended use.
“After reviewing the available studies,” she continued, “it is clear that women who take Avastin for metastatic breast cancer risk potentially life-threatening side effects without proof that the use of Avastin will provide a benefit, in terms of delay in tumor growth, that would justify those risks. Nor is there evidence that use of Avastin will help them live longer or improve their quality of life.”
Avastin will remain on the market as a treatment for other types of cancers, so doctors can use it off-label for breast cancer. But some insurers might no longer pay for the drug, which would put it out of reach of many women because it costs about $88,000 a year.
Medicare, however, has said it would continue to pay for the drug’s use in breast cancer.
The decision is a setback for the drug’s manufacturer, Genentech, which fought long and hard to keep the approval.
Analysts had previously estimated that loss of the breast approval could reduce sales at Roche, the Swiss company that bought Genentech in 2009, by about $1 billion. It appears that much of this decline has already occurred and Avastin appears to have lost its status as the world’s best-selling cancer drug to Roche’s own Rituxan, a medicine for lymphoma.
Genentech said in a statement that it was “disappointed with this outcome.” It said it would continue with plans to conduct another clinical trial in an effort to regain approval. It also said it would continue to provide help through its patient-support programs to breast cancer patients who might not be able to afford the drug.
Dr. Hamburg’s decision, outlined in a 69-page memorandum, agrees with the unanimous recommendation to revoke the approval made by an F.D.A. advisory committee in June, after an emotion-packed two-day hearing. The fact that it took Dr. Hamburg nearly five months to make a final decision attests to the sensitivity and complexity of the issue.
Some women who say the drug has been keeping them alive have pleaded desperately for the approval to be retained. So the revocation risked subjecting the Obama administration to criticism of being cruel. In addition, some Republicans had cited the possible action as an example of rationing under health care reform. (The F.D.A. has insisted that cost issues were not considered.)
Yet pressure came from the other direction as well. The administration had pledged to make scientific decisions on the basis of science. That made it difficult for Dr. Hamburg to go against the conclusions of the F.D.A.’s own staff and the strong recommendations of the outside experts on its advisory committee.
